Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

The blockbuster drug Enhertu from AstraZeneca and Japanese drugmaker Daiichi Sankyo stalled the growth of a common type of breast cancer by more than a year in a large late-stage trial when used ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer ... stage candidates from AstraZeneca and Radius ...